If you purchased Atripla®, Biktarvy®, Complera®, Descovy®, Evotaz®, Genvoya®, Odefsey®, Prezcobix®, Stribild®, Symtuza®, Truvada®, or Viread®, a class action lawsuit may affect your rights.
If you are a member of one or both classes, your legal rights will be affected whether you act or don’t act, so please read this notice carefully.
The End-Payor Plaintiffs (those who brought this lawsuit) allege that the manufacturers of these
drugs—Defendants Gilead, Janssen, and BMS (which has settled with Plaintiffs)—impaired or delayed the availability of allegedly less-expensive generic versions of certain of the Products
and, more generally, engaged in anticompetitive conduct to keep the prices of certain of the Products high. All of the Defendants deny the essential allegations of the Complaint.
The Court has certified three Damages Classes and three Injunctive Classes in this lawsuit (the “Classes”). The Damages Classes are made up of third-party payors (“TPPs”) only
(i.e., not individual consumers); the Injunctive Classes are made up of both TPPs and consumers.
Exclusion Deadline
March 15, 2023